BILL ANALYSIS                                                                                                                                                                                                    



                                                                       



           ------------------------------------------------------------ 
          |SENATE RULES COMMITTEE            |                  SCR 119|
          |Office of Senate Floor Analyses   |                         |
          |1020 N Street, Suite 524          |                         |
          |(916) 651-1520         Fax: (916) |                         |
          |327-4478                          |                         |
           ------------------------------------------------------------ 
           
                                         
                                 THIRD READING


          Bill No:  SCR 119
          Author:   Wolk (D), et al
          Amended:  As introduced
          Vote:     21

           
          WITHOUT REFERENCE TO COMMITTEE OR FILE


           SUBJECT  :    Plasma Protein Therapies Month

           SOURCE  :     Plasma Protein Therapeutics Association


           DIGEST  :    This resolution designates September 2010 as  
          Plasma Protein Therapies Month and encourages the people of  
          the State of California to observe the month with  
          appropriate programs and activities.

           ANALYSIS  :    This resolution makes the following  
          legislative findings:

          1. Patients with rare, chronic, genetic diseases and  
             disorders across the United States rely upon access to  
             plasma-derived and recombinant analog therapies, known  
             collectively as "plasma protein therapies," to treat  
             life-threatening conditions.
           
          2. These disorders, including, but not limited to,  
             hemophilia, von Willebrand disease, primary  
             immunodeficiency diseases, Chronic Inflammatory  
             Demyelinating Polyneuropathy, Kawasaki disease, and  
             alpha 1-antitrypsin deficiency, are most effectively  
                                                           CONTINUED





                                                               SCR 119
                                                                Page  
          2

             treated with plasma protein therapies.
           
          3. Individuals afflicted with these rare disorders require  
             access to the full range of plasma protein therapies to  
             help ensure the best possible clinical outcomes.  These  
             individuals benefit from access to the appropriate  
             providers.  These individuals need access to options in  
             pharmacy services and the delivery of home supported  
             services.

          4. Access to comprehensive care has been shown to markedly  
             improve patient outcomes.
           
          5. There are 10 plasma collection centers in the State of  
             California certified under the International Quality  
             Plasma Program where healthy, committed donors provide  
             plasma used to manufacture high impact, life saving  
             therapies.

          This resolution designates the month of September 2010 as  
          "Plasma Protein Therapies Month" and the people of the  
          State of California are encouraged to observe this month  
          with appropriate programs and activities.

           FISCAL EFFECT  :    Fiscal Com.:  No

           SUPPORT  :   (Verified  8/2/10)

          Plasma Protein Therapeutics Association (source)


          CTW:mw  8/2/10   Senate Floor Analyses 

                         SUPPORT/OPPOSITION:  SEE ABOVE

                                ****  END  ****